Skip to main content
HAVN Life Sciences Inc. logo

HAVN Life Sciences Inc. — Investor Relations & Filings

Ticker · HAVN ISIN · CA4196213058 LEI · 8945000AB697WU0RRI15 CSE Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2023-11-10 Regulatory Filings
Country CA Canada
Listing CSE HAVN

About HAVN Life Sciences Inc.

https://havnlife.com/

HAVN Life Sciences Inc. is a biotechnology company focused on the research, standardized extraction, and formulation of psychoactive compounds derived from plants and fungi. The company operates HAVN Labs, which is dedicated to building a quality-controlled psychedelic supply chain for clinical researchers. Its primary activities include the standardized extraction of compounds for the creation of Active Pharmaceutical Ingredients (APIs) and the development of formulations, particularly for microdosing therapies. HAVN Life supports innovative treatments addressing mental health disorders and aims to unlock human performance through evidence-informed research. The company also develops and distributes natural health care products.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the British Columbia Securities Commission has issued a cease trade order against HAVN Life Sciences Inc. due to the company's failure to file its audited financial statements and interim financial results by the required deadlines. The document discusses regulatory actions, filing defaults, and the status of the audit and filings but does not contain any actual financial statements or detailed financial data. It is an announcement related to regulatory compliance and trading restrictions rather than a financial report or filing itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2023-11-10 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document announces the results of an Annual Meeting of Shareholders, including the election and re-election of directors, re-appointment of auditors, approval of resolutions, and renewal of executive officers. It also announces the extension of warrants subject to exchange approval. The content focuses on shareholder meeting outcomes and management appointments rather than detailed financial data or comprehensive financial performance. The document is approximately 6970 characters, which is sufficient to contain substantive information about meeting results but does not include full financial statements or detailed analysis. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings. The warrant extension is a capital/financing update but is secondary to the main content about the meeting results. Therefore, the best classification is DVA with high confidence.
2023-10-26 English
News release - English.pdf
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the expected filing date of the company's Annual Report (Form 20-F) and related annual filings, including audited consolidated financial statements and management discussion and analysis for the year ended April 30, 2023. It discusses delays due to auditor staffing shortages and regulatory cease trade orders but does not contain the actual annual report or financial statements. The document is relatively short (6620 characters) and serves as an announcement about the timing of the report filing rather than the report itself. Therefore, it fits the category of Report Publication Announcement (RPA).
2023-10-26 English
News release - English.pdf
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the expected filing date of the company's Annual Report (Form 20F) and related annual filings, including audited consolidated financial statements, management's discussion and analysis, and certifications. It discusses delays due to auditor staffing shortages and regulatory cease trade orders. The document does not contain the actual annual report or financial statements but rather informs about the timing and status of the filing. The length is about 7,000 characters, which is relatively short and consistent with an announcement rather than the full report. Therefore, this document is best classified as a Report Publication Announcement (RPA).
2023-10-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a bi-weekly status update regarding a Management Cease Trade Order (MCTO) due to delays in filing the company's annual financial statements and interim filings. It references regulatory guidelines (National Policy 12-203) and discusses the status of filings and trading restrictions on insiders. The document does not contain actual financial statements or detailed financial analysis but is a regulatory update on filing delays and trading restrictions. It is not the annual report or interim report itself, nor is it a certification letter. It is a regulatory announcement about the status of filings and compliance with securities commission orders. Therefore, it fits best under Regulatory Filings (RNS).
2023-09-19 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 51-102F3 MATERIAL CHANGE REPORT filed by HAVN Life Sciences Inc. It announces a material change related to the anticipated delay in filing the company's audited annual financial statements, management discussion & analysis, and CEO/CFO certificates for the fiscal year ended April 30, 2023. The report details the regulatory context, including the application and granting of a Management Cease Trade Order (MCTO) by the British Columbia Securities Commission (BCSC) due to the delay. The document is a regulatory disclosure about a material change and filing delay, not the actual annual report or financial statements themselves. It is a formal regulatory filing notifying stakeholders of the material change and compliance status. The document length is 4402 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-30 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.